INTRODUCTION
The complement system is traditionally considered to be a component of the innate immune system. In the context of transplantation, complement activation is a well recognized effector mechanism underlying alloantibody-mediated rejection [1, 2] . Evidence published since the late 1990s has expanded our understanding of complement's role in allograft injury. Complement participates in the pathogenesis of ischemia-reperfusion injury, modulates alloreactive T-cell immunity, and contributes to chronic allograft failure. Herein, we summarize the current state of knowledge regarding complement and transplant injury, highlighting new findings published since 2013.
OVERVIEW OF COMPLEMENT
The complement system is comprised of soluble and membrane-bound proteins, including zymogens, receptors, and regulators that link innate and adaptive immunity. The complement cascade, outlined in Fig. 1 , can be activated via the lectin pathway, the classical pathway, and the alternative pathway [3] . Convergence at a central amplification step forms multimeric C3 convertases [3] , which cleave C3 to C3a and C3b, the latter initiating formation of C5 convertase and, ultimately, the membrane attack complex (MAC, C5b-9). Soluble and surface bound split products, including C3a, C3b, iC3b, C3dg, and C5a mediate inflammation by directly lysing target cells, serving as chemoattractants, functioning as opsonins, and activating innate immune cells, including macrophages and neutrophils [4] .
Regardless of the initiating pathway, cascade amplification predominantly occurs at the C3 convertase step and is driven by the alternative pathway ( Fig. 1 ). Circulating/systemic complement proteins are produced by the liver but complement proteins are also produced by tissue-resident (e.g., tubular cells in the kidney [5] ) and migratory/immune cells, including T cells and antigen presenting cells (APCs [6] ). Under physiological conditions, complement activation is tightly regulated by several membrane-bound and soluble regulatory proteins to prevent injury to selfcells [4] (see Fig. 1 ). The protective effects of complement regulators can be overcome under pathogenic conditions, although precise mechanisms remain to be elucidated.
COMPLEMENT AND ISCHEMIA-REPERFUSION INJURY
Posttransplant ischemia induces tissue hypoxia, mitochondrial damage, and ATP depletion, followed by the generation of free oxygen radicals and endothelial damage upon reperfusion [7] . Subsequent inflammation is partially dependent upon complement activation [8] [9] [10] [11] . Work performed in
KEY POINTS
The complement system negatively affects allograft survival via multiple mechanisms.
Serum complement participates in antibody-initiated allograft injury, locally produced, graft-derived, complement and serum complement mediate ischemiareperfusion injury, and immune cell-derived complement crucially modulates effector and regulatory T cells.
Targeting complement has the potential to attenuate alloimmunity and allograft injury thereby improving outcomes in human transplant recipients. murine kidney transplant models revealed that donor kidney-derived C3, and not systemic recipient C3, is the predominant complement source driving ischemia-reperfusion injury [12] . Data from animal models and humans suggest that the donor brain death upregulates complement activation in the donor kidney prior to organ removal [13] . The mechanisms through which complement mediates ischemia-reperfusion injury include signals transmitted via C3a/C5a interactions with their receptors, C3aR/C5aR [14] , including (but not limited to) C3a/C3aR-dependent production of chemokines by renal tubular epithelial cells [15] . The complementdependent inflammation associated with ischemiareperfusion injury can amplify adaptive alloimmunity [16] and can facilitate T-cell infiltration into the allograft [17, 18] , together potentially resulting in negative long-term consequences to the transplanted organ ( Fig. 2a ).
MBL+
Understanding the signals that initiate complement activation following posttransplant ischemia-reperfusion injury has the potential to guide development of preventive therapies. A 2013 publication showed significantly reduced kidney injury in mannan-binding lectin serine peptidase 2 (MASP2)-deficient mice implicating the lectin pathway [19 & ]. Cardiac ischemia-reperfusion injury also results in mannose lectin pathway-dependent complement activation initiated by binding of natural immunoglobulin M antibodies reactive to tissue-expressed neoantigens (including nonmuscle myosin heavy chain II) that are upregulated/ exposed by hypoxia [20, 21] . Complement activation via the classical pathway also contributes to murine liver ischemia-reperfusion injury [22 & ]. Blocking complement activation with recombinant C1 esterase inhibitor (C1-INH), which disassociates the C1qrs complex ( Fig. 1 ), was effective in preventing ischemia-reperfusion injury in an animal model [23] . Therapeutic use of C1-INH improved survival and oxygenation in lung transplant patients with early signs of primary graft dysfunction [24 & ], supporting the need to more broadly test the efficacy of this agent to prevent ischemia-reperfusion injury in human transplant recipients.
Regardless of the activation pathway, amplification of the complement cascade initiated by ischemia reperfusion is alternative pathway dependent ( Fig. 1 ) and results in deposition of C3b on the ischemic graft cells [8] [9] [10] [11] . To target this mechanism, one research team conjugated a human complement regulatory protein CD35 (complement receptor 1, CR1, that binds to C3b/C4b and blocks complement activation at the C3 convertase step, Fig. 1 ) to a myristoylated peptidyl tail such that when administered by intravenous perfusion of the harvested organ it self-inserts into the lipid bilayer of the endothelial-cell membranes [25] . The approach inhibited local complement activation and limited posttransplant kidney ischemia-reperfusion injury in rats [26] . A human version, mirococept (APT070), is being tested for its efficacy to prevent posttransplant delayed graft function (DGF) [25] . Murine kidney ischemia-reperfusion injury was analogously prevented through treatment with a protein comprised of the complement regulator Crry ( Fig. 1 ) fused to complement receptor 2 (CR2). The CR2 component binds to the activation products iC3b/C3d/C3dg and thereby targets Crry-mediated complement inhibition specifically to sites of complement activation [13] . In an effort to target complement activation/amplification downstream of the C3 convertase, the humanized anti-C5 monoclonal antibody (mAb) Eculizumab is being tested for efficacy in preventing posttransplant kidney DGF (NCT01403389; NCT01919346).
COMPLEMENT AND ALLOREACTIVE T CELLS
Building upon the paradigm-shifting observation that wild type mice do not reject allografts from C3-deficient donors [27] , work from several groups uncovered an unexpected role for immune cellderived complement as a regulator of T-cell immunity ( Fig. 2b) . These studies showed that alternative pathway complement components are produced by T cells and APCs during cognate interactions (including but not limited to alloreactions) [6, 28, 29] . Locally produced C3a and C5a bind to their receptors expressed on the T-cell and the APC, resulting in signals that induce T-cell proliferation, inhibit T-cell apoptosis and drive APC upregulation of costimulatory molecules and cytokines, together amplifying T-cell immunity. C5a also has T-cell chemoattractant properties via direct binding to C5aR on T cells [30] and indirectly through chemokines upregulation [17] . Experiments performed in bone marrow chimeric mice indicate that these effects are mediated through immune cell-derived, rather than systemic, complement [6, 31] .
The effects of complement on alloreactive T cells impact transplant rejection. WT mice reject heart allografts deficient in the complement regulator DAF with accelerated kinetics through a process that is complement and T-cell dependent [31] . DAF physiologically restrains complement activation so its deficiency results in increased local production of C3a and C5a, which amplify alloreactive T-cell responses, explaining the above observations [29, 32] . DAF deficiency also accelerates T-celldependent skin graft rejection [28] and murine graft versus host disease (GVHD) [33] . Conversely, blocking C5a/C5aR interactions modulates T-celldependent rodent kidney transplant rejection [34] and murine GVHD [33] . Together with the observations that anti-C5 monoclonal antibody synergizes with cytotoxic T-lymphocyte-associated protein 4-immunoglobulin G fusion protein to prevent T-cell priming, limits T-cell trafficking to an allograft, and prolongs transplant survival in mice [17] , the body of work supports the conclusion that complement is a physiologically important regulator of pathogenic T-cell immunity that causes allograft rejection in animal models.
Analogous mechanisms apply to human T cells. C3a and C5a are generated during in-vitro cultures of human T cells responding to allogeneic dendritic cells and mediate alloimmune T-cell activation and expansion through the similar mechanisms delineated in the murine models [35, 36] . Pharmacological C5aR blockade reduced human antimouse GVHD scores, and inhibited T-cell responses in nonobese diabetic/severe combined immunodeficiency/gc null mouse recipients of human peripheral blood mononuclear cells [35] . Consistent with a role for complement as a crucial mediator of human T cells, patients genetically deficient in C3 have impaired Th1 differentiation [37 & ], and Compstatin, a C3 antagonist, was shown to inhibit human CD4 T-cell proliferation and polarization [38 & ]. One unique difference between mice and humans delineated in 2013 is that human CD4 þ T cells store intracellular C3. Upon T-cell receptor (TCR) activation cathepsin L-mediated production of C3 cleavage leads to autocrine C3a/C3aR signaling that sustains T-cell homeostasis and Th1/Th17 effector cell differentiation [39] . Another publication from the same group showed that C3a/C3aR signaling synergizes with lipopolysaccharide-transmitted signals on human monocytes to induce inflammasome activation, secretion of interleukin (IL)-1b and differentiation of IL-17-producing alloreactive T cells [40] . Together, the findings substantiate a key role for complement in human effector T-cell immunity.
Three 2013 publications showed that immune cell-derived complement inhibits induction, function, and stability of regulatory T cells (Treg), including those required for induction/maintenance of allograft tolerance [41] [42] [43] [44] (Fig. 2b) . Genetic or pharmacological blockade of C3aR/C5aR signal transduction in thymic-derived or natural Treg (nTreg) augments their in-vitro and in-vivo suppressive activity, abrogates autoimmune colitis, and prolongs allogeneic skin graft survival. Mechanisms involve C3a/C3aR and C5a/C5aR-induced phosphorylation of protein kinase B (also known as Akt) in the Treg and, as a consequence, phosphorylation of the transcription factor Foxo1, which results in lowered nTreg Foxp3 expression. Genetic deficiency or pharmacological blockade of C3aR/ C5aR signaling also augments the generation of Treg from naive precursors (induced or iTreg), stabilizes Foxp3 expression in iTreg, and resists iTreg conversion to interferon gamma/tumor necrosis factor alpha-producing effector T cells [42, 43] .
Immune cell-derived complement similarly modulates human Treg generation and function in vitro and in vivo [42] . Building upon previously published evidence that coengagement of the TCR and the complement regulator CD46 promote regulatory IL-10 production [45] , these new translational results underscore the crucial role of complement in modulating the balance between pathogenic and protective adaptive T-cell responses. They provide proof-of-concept that C3a/C3aR and C5a/C5aR ligations are viable targets for inhibiting alloreactive Teff and facilitating iTreg-mediated transplant tolerance. Whether complement antagonists can therapeutically control T-cell alloreactivity while simultaneously promoting Treg-induction, function, and stability to improve transplant outcomes in humans, remains to be determined.
COMPLEMENT AND ANTIBODY-MEDIATED TRANSPLANT INJURY
It has been known for decades that complement regulates immunoglobulin G (IgG) production [46] . The mechanism involves antigen-bound C3dg (a C3b cleavage product) binding to B-cell-expressed CR2 (CD21), which facilitates antigen presentation to B cells, and lowers the threshold for B-cell activation [47, 48] . C3-deficient mice fail to produce high-affinity IgG responses against major histocompatibility antigens in skin grafts [49] , confirming relevance to transplantation. Helper signals provided by T follicular helper (T FH ) cells support the differentiation of antigen-specific B cells into IgG-producing memory and plasma cells (reviewed in [50] ). Whether complement specifically impacts this process remains to be determined. Additional evidence for a link between complement and humoral immunity derives from a 2013 publication in which the authors demonstrated that complement-dependent ischemia-reperfusion injury amplifies development of humoral immune responses through a factor B-dependent mechanism [16] .
Complement activation is an established effector mechanism of alloantibody-mediated graft injury in rodent transplant models [2, 51] (Fig. 2c) . Donor-specific antibodies (DSA) initiate complement activation via the classical pathway. Subsequent anaphylatoxin production and MAC formation mediate inflammation and injury [52] . Similar mechanisms apply to human transplant recipients with donor-specific anti-human leukocyte antigen (HLA) antibodies [1, [52] [53] [54] .
A 2013 publication performed in a humanized mouse model of vascular transplantation provided new mechanistic insight into how complement links alloantibodies to allograft injury [55] . The investigators demonstrated that DSA bound to the donor human vascular endothelial cells caused complement deposition, activation, and MAC formation, and led to noncanonical NF-kB signaling. The complement activation did not result in cell lysis but instead initiated a proinflammatory gene programme that facilitated recruitment of alloreactive T cells required for the development of the allograft injury (Fig. 2c) .
Building upon the mechanistic studies, the availability of Eculizumab, a mAb that blocks the C5 convertase, led to clinical trials testing distal complement inhibition as a means to prevent and/or treat antibody-mediated rejection (ABMR) in humans (off label, not Food and Drug Administration approved). Eculizumab and plasma exchange reduced the incidence of ABMR in 26 sensitized kidney transplant recipients compared with a historical control group treated with a plasma exchange-based protocol alone [56] . Eculizumab also successfully reversed established ABMR in a small cohort [57] , although not universally [58 & ]. Later observations that ABMR can be resistant to Eculizumab [56] suggest that complement-mediated inflammation upstream of C5 or noncomplementmediated mechanisms (e.g., Fc receptor dependent) contribute to disease pathogenesis. Other reagents are being developed and tested. Among these, C1-INH partially inhibited ABMR in baboons [23] and a novel peptide inhibitor of C1 (PIC1) inhibited the antibody-initiated classical pathway and lectin pathway complement activation in rodents [59,60 & ].
With the recognition that DSA initiates complement activation and injury via the classical pathway, investigators hypothesized that detection of serum anti-HLA antibodies capable of binding C1q would enhance the prognostic utility of serum alloantibody analysis in kidney transplantation [61, 62] . The latest iteration of the single antigen bead technology currently used for detecting anti-HLA antibodies [63] additionally identifies those antibodies that bind C1q. A 2013 population-based study of 1016 kidney transplant recipients suggested that, among patients with anti-HLA antibodies, those who were C1q þ had the worst graft survival [64] . Similar associations were documented in heart [65] and in lung transplants [66] recipients. The clinical importance of C1q binding remains unclear as other reports suggest that C1q binding adds little prognostic information beyond standard DSA testing [67, 68] 
COMPLEMENT AND CHRONIC ALLOGRAFT INJURY
Mechanisms of late graft failure are complex and involve immune and nonimmune mechanisms [69] , but late graft loss is routinely associated with pathological evidence of progressive glomerulosclerosis, tubular atrophy, interstitial fibrosis, and arteriosclerosis [70, 71] . Evidence suggests that intragraft complement activation contributes to this pathogenic process (Fig. 2d ). C3-deficient kidney isografts transplanted into WT recipients were protected from toxin-induced tubular damage, proteinuria, and progressive renal failure, despite the presence of abundant circulating C3 [72] . Follow-up work showed that C3 is implicated in the activation of the renin-angiotensin system and in the epithelial to mesenchymal transition [73, 74] , supporting the concept that synthesis of complement components by renal epithelial cells is one critical mediator of tubular damage in proteinuria-associated renal disease. A 2013 publication suggested that cyclosporine A-induced microparticle release causes activation of alternative pathway complement in endothelial cells and kidney allograft injury [75] . In a 2014 study, the investigators showed that endothelialto-mesenchymal transition and associated renal fibrosis are linked to C3a/C5a via Akt activation [76 && ]. Together, these results raise the possibility that kidney-derived complement participates in the development of posttransplant kidney interstitial fibrosis and tubular atrophy (IF/TA). Murine studies indicate that complement activation contributes to chronic allograft injury in other organs, including obliterative bronchiolitis following lung transplantation [77] [78] [79] .
Associative evidence linking complement to progressive transplant injury in humans derived from studies of complement gene polymorphisms, serum complement concentrations, and transplant outcomes in humans. Specific C5 polymorphisms in both the donor and the recipient have been associated with worse late graft function, but interestingly not with the risk of acute rejection [80] . Although controversial, some additional evidence suggests that donor kidney expression of a specific polymorphic variant of C3 is associated with worse posttransplant outcomes [81, 82] . Low C4 gene copy numbers (<4) in kidney transplant recipients were also associated with increased allograft survival [83] . Additional evidence linking complement to chronic human allograft injury includes a proteomic analysis of kidney allograft tissue that showed strong associations between IF/TA and alternative pathway complement components [84] . An ongoing study of chronic Eculizumab therapy in kidney transplant recipients (NCT01327573) could potentially provide further insight into the role of complement as a mediator of progressive graft dysfunction and IF/TA.
CONCLUSION
The complement system is now firmly established as a pervasive mediator of transplant injury in animal models, and evidence supports that these newly recognized mechanisms apply to human transplant recipients (Fig. 2 ). This success of translational immunology along with the development of pharmacological agents that block human complement components and receptors [85, 86] will permit testing of the intriguing concept that targeting complement in all solid organ transplant recipients will improve graft survival and patient health. 
